GC
ITOS

Guggenheim Capital’s iTeos Therapeutics ITOS Stock Holding History

Guggenheim Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,861
Closed -$130K – 1911
2023
Q3 		$130K Buy
11,861
+656
+6% +$8.39K ﹤0.01% 1788
2023
Q2 		$148K Buy
11,205
+453
+4% +$6.46K ﹤0.01% 1808
2023
Q1 		$146K Sell
10,752
-10,732
-50% -$192K ﹤0.01% 1848
2022
Q4 		$420K Buy
+21,484
New +$420K ﹤0.01% 1558

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Guggenheim Capital's ITOS Position: Q4 2023 in Review

Guggenheim Capital sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 11,861 shares — an estimated $130K sold.

Guggenheim Capital first reported a position in ITOS in Q4 2022 and held it in 4 quarters. The position peaked at $420K in Q4 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Guggenheim Capital reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Guggenheim Capital sold 11,861 iTeos Therapeutics shares in Q4 2023, an estimated $130K.
  • Guggenheim Capital first reported a position in iTeos Therapeutics in Q4 2022 and held it in 4 quarters.
  • Guggenheim Capital's iTeos Therapeutics position peaked at $420K in Q4 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Guggenheim Capital's 13F filing for Q4 2023, filed 14 Feb 2024.